investor_presentation
Nutanix
Loading viewer...
investor_presentation
Format: PDF investor_presentation
Late-stage clinical biotech company developing first-in-class respiratory therapeutics, including two Phase 3 assets (AR-301 for acute pneumonia treatment and AR-320 for prevention) with ~$1 billion market opportunities. Presentation includes clinical data readouts and company overview with experienced management team.
investor_presentation
26 Pages
investor_presentation
34 Pages
Action Construction Equipment Ltd.
Generation Income Properties GIPR Investor Presentation April 2022
investor_presentationinvestor_presentation
17 Pages
Generation Income Properties, Inc.
investor_presentation
Nutanix